The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures. 

Witness Ge Bai, an associate professor at Johns Hopkins University’s Carey Business School and Bloomberg School of Public Health, said Congress should require drug makers to disclose their financial relationships with independent patient assistance programs and patient advocacy organizations and their free drug samples to clinicians. She said these transactions “can undermine the best interests of patients and their insurance plans while benefiting drug manufacturers financially.”   

Juliana Keeping, communications director for Patients for Affordable Drugs and the mother of a child with cystic fibrosis, also urged Congress to “eliminate the need for patient assistance programs by making drug costs affordable and cost-sharing manageable.” 

Tara O’Neill Hayes, director of human welfare policy for the American Action Forum, called for changes to the Part D benefit to remove “perverse incentives for insurers and drug manufacturers to benefit from high-cost drugs.” 

Steven Tananbaum, a senior fellow for the Council on Foreign Relations, recommended Congress remove incentives for drug makers to move profits and production offshore.

In December, the House of Representatives passed H.R. 3, legislation that would make changes to the Medicare program in an effort to lower prescription drug prices. 

Subcommittee Ranking Member Devin Nunes, R-Calif., said both parties “can work together to lower drug prices for families without reducing cures, but H.R. 3 is not the answer.” Instead, he voiced support for H.R. 19
 

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…